AmBisome® is indicated for the following:

• Empirical therapy for presumed fungal infection in febrile, neutropenic patients (see Pivotal Trials).
• Treatment of cryptococcal meningitis in HIV-infected patients (see Pivotal Trials).
• Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
• Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites (see Pivotal Trials).

See Dosage and Administration for recommended doses by indication.